Krynica Vitamin SA

Krynica Vitamin SA

GGPW:KVT
12.80
PLN
0.00
(0.00%)
0.53EPS
21.70P/E
140.27MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.98
13.49
13.61
16.79
21.98
24.22
36.43
32.26
30.78
29.32
31.66
29.08
27.27
Basic EPS, GAAP
0.07
1.11
0.12
0.43
0.41
0.58
4.62
1.27
1.07
-0.55
1
0.98
0.53
Free Cash Flow per Basic Share
0.05
-0.12
-0.23
0.2
-0.65
0.16
4.78
-0.6
-0.14
1.12
1.65
2.02
1.77
Dividend per Share
0.03
- -
0.74
0.17
0.24
0.66
2.24
1.47
- -
0.2
- -
0.27
0.27
Book Value per Share
3.15
4.95
4.14
4.4
4.57
4.49
6.57
6.35
7.42
6.68
7.67
8.38
8.45
Tangible Book Value per Share
3.1
4.9
4.09
4.37
4.54
4.26
6.38
6.13
7.23
6.51
7.41
8.06
8.12
Basic Weighted Avg Shares
170
12
12
12
12
12
12
12
12
12
12
12
12
Sales/Revenue/Turnover
167
165
167
206
269
297
446
395
377
359
388
356
334
Operating Margin (%)
10.83
10.25
3.81
3.64
3.17
3.88
17.56
5.92
5.54
2.4
4.57
5.86
3.79
Depreciation Expense
3
4
6
8
8
9
11
13
14
15
14
15
14
Net Income, GAAP
12
14
2
5
5
7
57
16
13
-7
12
12
6
Effective Tax Rate (%)
24.08
20.18
7.05
20.83
16.22
14.49
20.53
25.81
7.55
- -
11.44
19.4
11.94
Profit Margin (%)
7.23
8.2
0.9
2.55
1.88
2.38
12.68
3.94
3.47
-1.86
3.15
3.35
1.93
Working Capital
-2
10
-5
-5
-24
-31
-11
-19
-13
-22
-15
1
-4
LT Debt
11
7
17
14
17
33
28
32
29
23
17
14
9
Total Equity
39
61
51
54
56
55
81
78
91
82
94
103
103
Return on Invested Capital (%)
- -
21.35
4.55
6.89
7.61
8.57
49.36
11.39
10.58
- -
10.91
9.77
5.79
Return on Capital (%)
- -
20.89
2.73
7.2
6.38
7.62
49.11
12.62
10.87
- -
10.63
9.88
5.86
Return on Common Equity (%)
- -
27.34
2.7
10.04
9.19
12.72
83.5
19.67
15.5
-7.74
13.91
12.15
6.55

Capital Structure

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
23
16
19
LT Borrowings
11
11
9
LT Finance Leases
4
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
125
129
140

Working Capital

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
84
67
103
Cash, Cash Equivalents & STI
- -
- -
7
Accounts Receivable, Net
48
33
47
Inventories
32
29
43
Total Current Liabilities
82
66
107
Payables & Accruals
- -
- -
- -
ST Debt
23
16
19
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.6%
5.51%
9.18%
Free Cash Flow
125.22%
-199.71%
22.56%
Net Income, GAAP
37.28%
-104.99%
-2.29%
Sales/Revenue/Turnover
9.48%
-4.19%
-8.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
82
107
113
86
388
2025
80
- -
101
68
356
2026
85
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
0.49
0.54
0.06
1
2025
0.08
- -
0.41
-0.03
0.98
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
0.27
- -
0.27
2026
- -
- -
- -
- -
- -

Company Description

CEO
Piotr Czachorowski
Full Time Employees
350
Sector
Consumer non-durables
Industry
Beverages: non-alcoholic
Address
ul. Matyldy 35 Warsaw MZ Poland 03-606
IPO Date
Dec 16, 2015
Business
Krynica Vitamin S.A. Krynica Vitamin S.A. is a Poland-based contract manufacturer specializing in fast-moving consumer goods (FMCG), primarily producing non-alcoholic and low-alcoholic beverages; energy drinks, functional and isotonic drinks, metabolism-boosting beverages, vitamin dietary supplements, flavored waters, multifruit drinks with pulp, carbonated soft drinks (CSDs), alcopops, ciders, malt beverages, coffee drinks, and dairy drinks for global brands, private labels, and supermarket chains. Founded nearly 30 years ago and headquartered at ul. Matyldy 35 in Warsaw, Poland, the company operates one of Europe's largest production facilities with five lines capable of filling cans, PET bottles, and glass bottles at a capacity exceeding 400 million units annually; it serves an international customer base across 38 countries on all continents, including the US, UK, Germany, Poland, Czech Republic, and Slovakia, through its own R&D laboratory for product development and formula creation, as well as co-packing for cosmetics and sport supplements. Recent developments include a statute change registered in October 2025, multiple director transactions and share dealings by insiders such as Zinat in early October 2025, release of the H1 2025 interim report in September 2025, and a prior new long-term contract with Schweppes International Limited positioning it as one of few global suppliers.